OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Gadgeel on Longer-Term Data for Amivantamab Plus Lazertinib in EGFR+ NSCLC

September 27th 2024

Shirish M. Gadgeel, MD, on long-term follow-up data from MARIPOSA for amivantamab plus lazertinib in first-line EGFR-mutated non–small cell lung cancer.

Dr Ma on Mechanisms of Resistance to CDK4/6 Inhibitors in HR+ Breast Cancer

September 27th 2024

Cynthia X. Ma, MD, PhD, discusses current unmet needs associated with the use of CDK4/6 inhibitors in the treatment of breast cancer.

Dr Sands on Consolidation Durvalumab as a Potential New SOC for LS-SCLC After Chemoradiation

September 27th 2024

Jacob Sands, MD, discusses consolidation therapy durvalumab as a new standard of care in limited-stage small cell lung cancer.

Dr Lee on Safety Considerations for Enfortumab Vedotin in Metastatic Urothelial Cancer

September 27th 2024

John K. Lee, MD, PhD, discusses safety considerations for enfortumab vedotin in the treatment of metastatic urothelial cancer.

Dr Drakaki on Nivolumab/Ipilimumab in Advanced RCC With Sarcomatoid Differentiation

September 27th 2024

Alexandra Drakaki, MD, PhD, discusses nivolumab plus ipilimumab in the treatment of renal cell carcinoma with sarcomatoid differentiation.

Dr Dorritie on Acalabrutinib With/Without Obinutuzumab in Treatment-Naive CLL

September 27th 2024

Kathleen A. Dorritie, MD, discusses acalabrutinib with or without obinutuzumab vs obinutuzumab plus chlorambucil in treatment-naïve CLL.

Dr Lorusso on the Use of Selective Glucocorticoid Receptor Modulators in Recurrent Ovarian Cancer

September 27th 2024

Domenica Lorusso, MD, PhD, discusses the rationale for investigating relacorilant combined with nab-paclitaxel in recurrent, platinum-resistant ovarian cancer.

Dr Necchi on the Efficacy and Safety of TAR-200 Plus Cetrelimab in MIBC

September 26th 2024

Andrea Necchi, MD, discusses an analysis of the SunRise-4 trial evaluating TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer.

Dr Xu on the Preliminary Efficacy of SHR-A1904 in Gastric/GEJ Cancer

September 26th 2024

Ruihua Xu, MD, PhD, discusses data from a phase 1 trial investigating the CLDN18.2-targeted antibody-drug conjugate SHR-A1904 in gastric/GEJ cancer.

Dr Van Akkooi on the Prognostic Value of Minimal Sentinel Node Tumor Burden in Melanoma

September 26th 2024

Alexander C. Van Akkooi, MD, PhD, FRACS, discusses the prognostic value of minimal sentinel node tumor burden in melanoma.

Dr Choueiri on Initial Efficacy Data With NKT2152 in Pretreated ccRCC

September 26th 2024

Toni K. Choueiri, MD, discusses early findings from a phase 1/2 trial evaluating NKT2152 in previously-treated advanced clear cell renal cell carcinoma.

Dr Armenian on Improving Outcomes and Reducing AEs in Pediatric Oncology

September 26th 2024

Saro H. Armenian, DO, MPH, discusses treatment advancements that have helped reduce long-term adverse effects for patients in pediatric oncology.

Dr McKean on the Efficacy of Fianlimab Plus Cemiplimab in Advanced Melanoma

September 26th 2024

Meredith McKean, MD, discusses the efficacy of fianlimab given in combination with cemiplimab for patients with advanced melanoma.

Dr Ng on the Addition of Vitamin D to Bevacizumab Plus Chemotherapy in mCRC

September 26th 2024

Kimmie Ng, MD, MPH, discusses the addition of vitamin D to standard chemotherapy plus bevacizumab in patients with untreated metastatic colorectal cancer.

Dr Partridge on Unique Treatment Challenges for Young Patients with ER+/Node-Positive Breast Cancer

September 25th 2024

Ann H. Partridge, MD, MPH, discusses unique challenges associated with very young patients who have ER+/node-positive breast cancer.

Dr Strickler on the Safety and Efficacy of Telisotuzumab Adizutecan in Gastric/GEJ Cancer

September 25th 2024

John H. Strickler, MD, discusses the efficacy and safety of telisotuzumab adizutecan in patients with MET gene–amplified gastric/GEJ cancer.

Dr Aggarwal on Data for CAN-2409 Plus Valacyclovir and Continued ICIs in NSCLC

September 25th 2024

Charu Aggarwal, MD, MPH, FASCO, on data for CAN-2409 plus valacyclovir with continued immune checkpoint inhibitors in advanced non–small cell lung cancer.

Dr Saad on the Efficacy and Safety of Darolutamide Plus ADT in mHSPC

September 25th 2024

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy findings from the ARANOTE trial in patients with metastatic hormone-sensitive prostate cancer.

Dr Armenian on Challenges With Transitioning from Pediatric to Adult Cancer Care

September 25th 2024

Saro H. Armenian, DO, MPH, discusses the difficulties that patients face when transitioning from pediatric to adult cancer care, highlighting unmet needs.

Dr Morgans on Recent Adjustments to Medicare Part D to Improve Treatment Access in Prostate Cancer

September 24th 2024

Alicia Morgans, MD, MPH, discusses recent adjustments to Medicare Part D rules, emphasizing their positive impact on out-of-pocket costs for patients with prostate cancer.